Replies to post #45668 on Biotech Values

[Jonathan Robinson]

Dew,

Why not do the simple question, which relates directly to T and ask about its revenues in 2008 or 2009?

<$250
250-499
500-749
750-999
>999

Jon

[masterlongevity]

OK. Point taken. Since Avonex is still the market leader in RRMS, even over copaxone, I think we should just use Avonex

Avonex
Tysabri
Copaxone

According to my research
Rituxan - estimated launch H1 2009
FTY720- estimated launch H1 2009


although if Rituxan data is positive in PPMS (H1 2008), i think it will be used heavily off-label


Can we combine Rituxan and FTY20 and call them new products?